ASCO/EHA/ICML 2021 – Carol Moreno
Carol Moreno highlights the CLL study results from EHA and ICML, enlarges on fixed-duration regimens in CLL treatment, the importance of long-term follow-up findings obtained in important trials such as CLL14 and ELEVATE-TN as well as data from the ALPINE and ELEVATE-RR studies and shares her thoughts on the role of new agents such as zanubrutinib in the overall treatment landscape.
Here is the full ASCO/EHA/ICML 2021 report.
More posts
Zanubrutinib in relapsed/refractory marginal zone lymphoma: MAGNOLIA
Zanubrutinib in relapsed/refractory marginal zone lymphoma: MAGNOLIA B-cell rec
Mantle cell lymphoma: improving outcomes in difficult-to-treat patient populations
Mantle cell lymphoma: improving outcomes in difficult-to-treat patient populations
Extending anti-PD-1–based options in the setting of Hodgkin lymphoma
Extending anti-PD-1–based options in the setting of Hodgkin lymphoma Patients w
Successful inhibition of PI3K, BTK, BCL2 and other targets in various B-cell malignancies
Successful inhibition of PI3K, BTK, BCL2 and other targets in various B-cell malign
Waldenström’s macroglobulinemia: outcome optimization via combinations
Waldenström’s macroglobulinemia: outcome optimization via combinations Final an
CLL/SLL: current perspectives across a range of potent agents
CLL/SLL: current perspectives across a range of potent agents ALPINE: zanubruti
